Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

DSIP

A natural sleep peptide. Pushes you toward deeper sleep and tones down nighttime stress hormones. Inject before bed.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Amino acid sequence

WAGGDASGE
9 residues
Molecular formula
C₃₅H₄₈N₁₀O₁₅
Average mass
848.8 Da
CAS number
62568-57-4
Registry
PubChem CID 68816
Receptor / pathway
Delta sleep-inducingpathway
Formula, mass and identifiers from PubChem CID 68816. Mass recomputed from the sequence.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nine-amino-acid neuropeptide found in the brain, hypothalamus, and pituitary gland.

What problem it targets: It targets severe insomnia, disrupted circadian rhythms, high nighttime cortisol spikes, chronic physiological stress, and chronic pain syndromes.

What It Does

• Restores natural slow-wave deep sleep: Crosses the blood-brain barrier to synchronize EEG delta rhythms in the brain, restoring restorative Stage 3 and Stage 4 deep sleep.

• Regulates the HPA axis: Modulates stress response pathways by lowering elevated nighttime ACTH and cortisol levels, bringing the nervous system out of chronic overdrive.

• Modulates central pain perception: Interacts with endogenous opioid and GABAergic pathways, exerting mild analgesic and mood-stabilizing effects.

• Realistic expectations: It is not a heavy narcotic sedative; it will not knock you out instantly. Instead, it re-trains natural sleep patterns over a few weeks, leading to deeper, uninterrupted sleep.

Reconstitution

Vial sizeBAC water / SolventConcentration
2 mg+ 0.4 mL5 mg/mL
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL

Protocol

PhaseFrequencyDoseUnits (2 mg/mL)Units (3.33 mg/mL)Notes
Weeks 1–2Nightly200 mcg10u6.0uStart low and assess how your body responds before increasing.
Weeks 3–8Nightly200–500 mcg10–25u6.0–15.0uEffective range.
Off2–4 weeks–––Essential break between cycles. Skipping leads to tolerance and diminishing returns. Cycle: 4–8 weeks on, 2–4 weeks off. Timing: Pre-bed nightly, 15–30 min before sleep. Evidence: minimal human data; no dosing RCT. By sex: Unisex sleep peptide, same protocol for men and women, no cycle effect.

Handling & Stacking

Injection site
SubQ abdomen.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within ~10–14 days (structure-based estimate, no published data); potency fades before the 28- day sterility limit, so keep it cold and dark and use it sooner.
  • Protect from light.
Side effects
Sedation (expected), headache (occasional), vivid dreams.
What to expect
  • Deeper, more restorative sleep typically within the first few doses.
  • Reduced overnight cortisol.
  • Vivid dreams in some users.
  • Supply math 2mg → 12 vials | 5mg → 5 vials | 10mg → 3 vials (8-wk @ 500 mcg × 7/wk)
Pairs well with
Melatonin (sleep architecture); Glycine (deep-sleep amplification); GHK-Cu (recovery during sleep)
Avoid
Active or history of cancer (theoretical GH-related concern). Pregnancy / nursing
Approved drug
Approved insomnia drugs: the orexin blockers suvorexant (Belsomra), lemborexant (Dayvigo) and daridorexant (Quviviq); low-dose doxepin (Silenor); ramelteon (Rozerem); and zolpidem.

Safety & Patient Education

Contraindications
Pregnancy, lactation, active or history of cancer (theoretical GH-related concern)
Warnings
Limited human data. PCAC REJECTED it (as “emideltide”) from the 503A bulks list, 6–7 (Jul 2026); the only one of seven peptides voted down.
Drug interactions
CNS depressants (benzodiazepines, Z-drugs, barbiturates, opioids, alcohol): additive sedation; avoid same-night combo or reduce dose Other sleep agents (melatonin, Epithalon): redundant rather than additive; pick one per cycle Sedating antidepressants (mirtazapine, trazodone, doxepin, amitriptyline): additive sedation; coordinate timing Stimulants (caffeine, ADHD meds): mechanistically opposed; not harmful but blunts effect Antihypertensives: theoretical additive nocturnal BP drop, monitor if combining at high doses
Labs
Compound-specific: CBC + CMP baseline; no compound-specific markers routinely required
Stop criteria
Excessive sedation, vivid dreams disturbing sleep, persistent daytime grogginess
References
researchdosing · peptidedosages · PubMed · thepeptidereport · peptides.id